SHSangjo Han

Sangjo Han

*This is an algorithmically generated author record based on publicly available information.

Sangjo Han has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative studies for developing protein based cancer prediction model to maximise the ROC-AUC with various variable selection methods

    by Taesung Park, Seungyeoun Lee, Youngsoo Kim, Hyunsoo Kim, Wooil Kwon, Jin Young Jang, Sun Whe Kim, Sung Gon Yi, Junghyun Namkung, Sangjo Han, et al.

    The era of protein data analysis is coming with more accurate quantification experiments such as the multiple reaction monitoring (MRM). Protein is easier to obtain than the other genetic variants or gene expression data, which makes it more suitable for early diagnosis of cancer. Each patient has unique patterns of protein data, which makes it imperative for the researcher to select the effective markers to construct a consistent model to predict the patients. This research focuses on finding the most effective variable selection method to be applied in the early diagnosis of the pancreatic cancer. In the process, we compare classical selection methods (stepwise selection based on AIC, BIC), machine learning based selection method (support vector machine recursive feature selection; SVM-REF), and stepwise selection method using the area under the receiver operating characteristic curve (Step-AUC). Based on the simulation and real data analysis, we suggest a Step-AUC method to maximise the prediction performance of the early diagnosis by protein data.

  • Open Access

    Integrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer

    by Min-Seok Kwon, Yongkang Kim, Seungyeoun Lee, Junghyun Namkung, Taegyun Yun, Sung Gon Yi, Sangjo Han, Meejoo Kang, Sun Whe Kim, Jin-Young Jang, et al.

    MicroRNA (miRNA) expression plays an influential role in cancer classification and malignancy, and miRNAs are feasible as alternative diagnostic markers for pancreatic cancer, a highly aggressive neoplasm with silent early symptoms, high metastatic potential, and resistance to conventional therapies. In this study, we evaluated the benefits of multi-omics data analysis by integrating miRNA and mRNA expression data in pancreatic cancer. Using support vector machine (SVM) modelling and leave-one-out cross validation (LOOCV), we evaluated the diagnostic performance of single- or multi-markers based on miRNA and mRNA expression profiles from 104 PDAC tissues and 17 benign pancreatic tissues. For selecting even more reliable and robust markers, we performed validation by independent datasets from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) data depositories. For validation, miRNA activity was estimated by miRNA-target gene interaction and mRNA expression datasets in pancreatic cancer. Using a comprehensive identification approach, we successfully identified 705 multi-markers having powerful diagnostic performance for PDAC. In addition, these marker candidates annotated with cancer pathways using gene ontology analysis. Our prediction models have strong potential for the diagnosis of pancreatic cancer.


  • Open Access

    Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer

    by Shinuk Kim, Mee Joo Kang, Seungyeoun Lee, Soohyun Bae, Sangjo Han, Jin-Young Jang, Taesung Park

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal tumors and usually presented with locally advanced and distant metastasis disease, which prevent curative resection or treatments. In this regard, we considered identifying molecular subtypes associated with clinicopathological factor as prognosis factors to stratify PDAC for appropriate treatment of patients. In this study, we identified three molecular subtypes which were significant on survival time and metastasis. We also identified significant genes and enriched pathways represented for each molecular subtype. Considering R0 resection patients included in each subtype, metastasis and survival times are significantly associated with subtype 1 and subtype 2. We observed three PDAC molecular subtypes and demonstrated that those subtypes were significantly related with metastasis and survival time. The study may have utility in stratifying patients for cancer treatment.